UTILITY OF ASSESSING TSH RECEPTOR ANTIBODY IN GRAVES' DISEASE

评估 TSH 受体抗体在格雷夫斯病中的效用

• 批准号: 7607279
• 负责人: Rosalind Brown
• 金额: $ 4.2万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607279
• 关键词: Adolescent; Affect; Biological Assay; Child; Clinical; Clonality; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Disease; Disease Progression; Enzyme-Linked Immunosorbent Assay; Fc Receptor; Funding; Grant; Graves' Disease; Heterogeneity; Hormonal; Hyperthyroidism; Individual; Institution; Measures; Medical; Newly Diagnosed; Patients; Research; Research Personnel; Resources; Severities; Source; TSH receptor antibody; Thyroid Function Tests; Thyrotropin Receptor; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this proposal will be to: 1) Prospectively follow a group of children and adolescents with newly diagnosed Graves' disease 2) Measure thyroid function tests (T4, Free T4, Total T3, and TSH), TSH receptor antibodies (by both ELISA and bioassay), and TSH receptor antibody oligoclonality (as assessed by lambda/kappa ratio) at diagnosis, 6 months, and 12 months 3) Determine whether initial severity of hyperthyroidism (as determined by both clinical and hormonal parameters) is related to initial TSH receptor Ab potency and/or oligoclonality or both 4) Determine whether TSH receptor Ab titer at 6 months and at 12 months is related to: a) initial severity of hyperthyroidism (as determined by both clinical and hormonal parameters) b) initial TSH receptor Ab potency (by both ELISA and bioassay) c) initial TSH receptor Ab oligoclonality, as well as TSH receptor Ab oligoclonality at 6 months and 12 months 5) Characterize the course of TSH receptor Ab heterogeneity at diagnosis, 6 months and 12 months in individual patients; We hypothesize that: 1) Amongst children with Graves' disease, 75% will have TSH receptor Abs that are polyclonal as assessed by lambda/kappa ratio and 25% will have oligoclonal Abs 2) Oligoclonal Abs are more potent and affected patients have more severe disease and are less likely to remit 3) Those patients who have the most severe disease at diagnosis will have the highest TSH receptor Ab titers and will be less likely to remit on medical therapy 4) 25% of patients will have a change in clonality with disease progression.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该提案的目标将是： 1）前瞻性跟随一群新诊断为Graves疾病的儿童和青少年 2）测量甲状腺功能测试（T4，Free T4，Total T3和TSH），TSH受体抗体（通过ELISA和Bioassay）以及TSH受体抗体的寡聚性（如Lambda/kappa比率评估） 3）确定甲状腺功能亢进症的初始严重程度（由临床和激素参数确定）是否与初始TSH受体AB效力和/或寡聚性有关或两者都有关 4）确定在6个月和12个月时在6个月和12个月时是否与： a）甲状腺功能亢进的初始严重程度（由临床和激素参数确定） b）初始TSH受体AB效力（ELISA和Bioassay） C）初始TSH受体AB寡聚性以及6个月零12个月的TSH受体AB寡聚性 5）表征诊断时TSH受体AB异质性的过程，单个患者为6个月零12个月； 我们假设这一点： 1）在患有坟墓疾病的儿童中，有75％的tsh受体ABS是由Lambda/kappa比率评估的多克隆的TSH受体ABS，而25％的TSH受体ABS将具有寡克隆ABS 2）寡克隆ABS更有效，受影响的患者患有更严重的疾病，并且不太可能释放 3）那些在诊断时患有最严重疾病的患者的TSH受体AB滴度最高，并且对医疗治疗的份额不太可能 4）25％的患者将随着疾病进展的克隆性改变。